Randomised trial comparing dopamine agonist, MAOB inhibitor and COMT inhibitor as adjuvant therapy in later Parkinson’s disease (PD)
Objective: The PD MED trial aimed to determine which class of drug provides the best patient-rated quality of life (QoL) when used as adjuvant therapy…AntiParkinsonian effects of AG-0029 in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated macaque model of Parkinson’s disease
Objective: To assess the motor functions in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated macaques following acute administration of AG-0029. Background: Parkinson's disease (PD), in which there is widespread degeneration…
- « Previous Page
- 1
- …
- 11
- 12
- 13